PAR-23-300: Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $100,000 to the applicants described in the notice. Applications closed on May 21, 2025.
From the official notice on Grants.gov, last changed May 22, 2025. Checked November 7, 2026.
- Award ceiling$100,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeG11
- Clinical trialsNot allowed
Application due dates, page limits and budget limits are set in the notice. Read PAR-23-300 in the NIH Guide.
Key dates
| Posted | September 11, 2023 |
|---|---|
| Deadline | May 21, 2025 |
| Archived by Grants.gov | June 20, 2025 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations).
Is this a realistic fit?
- Past Allergy and Infectious Diseases Research awards averaged $1.6 million; this notice allows up to $100,000 per award.
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this notice of funding opportunity (NOFO) is to invite applications from research institutions in low- and middle-income countries (LMICs) to provide senior administrators from these institutions with advanced training in the management of NIH grants. The goal is to improve oversight of NIAID grant awards and compliance with NIH funding policies and Federal research funding requirements for NIAID-supported foreign institutions in LMICs.
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-23-300 still open?
No. It closed on May 21, 2025.
Who can apply for Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed)?
Closed May 21, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $100,000 each.
Who has won Allergy and Infectious Diseases Research grants before?
The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)